Generic Drug-EMEA Market Status and Trend Report 2013-2023
Report Summary
Generic Drug-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Generic Drug industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole EMEA and Regional Market Size of Generic Drug 2013-2017, and development forecast 2018-2023
Main market players of Generic Drug in EMEA, with company and product introduction, position in the Generic Drug market
Market status and development trend of Generic Drug by types and applications
Cost and profit status of Generic Drug, and marketing status
Market growth drivers and challenges
The report segments the EMEA Generic Drug market as:
EMEA Generic Drug Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Europe
Middle East
Africa
EMEA Generic Drug Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Pure (Non-branded) Generics
Branded Generics
Super Generics
EMEA Generic Drug Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Cardiovascular & Hypertension
Dermatology
Diabetes
Rheumatology
Oncology
Gastrointestinal
Others
EMEA Generic Drug Market: Players Segment Analysis (Company and Product introduction, Generic Drug Sales Volume, Revenue, Price and Gross Margin):
Teva Pharma.
Novartis company
Mylan
Allergan
Hospira
Dr. Reddy?s Lab.
Stada
Greenstone
Par Pharma
Sun Pharmaceutical
Aspen Pharmacare
Fresenius
Lupin
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Generic Drug-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Generic Drug industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole EMEA and Regional Market Size of Generic Drug 2013-2017, and development forecast 2018-2023
Main market players of Generic Drug in EMEA, with company and product introduction, position in the Generic Drug market
Market status and development trend of Generic Drug by types and applications
Cost and profit status of Generic Drug, and marketing status
Market growth drivers and challenges
The report segments the EMEA Generic Drug market as:
EMEA Generic Drug Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Europe
Middle East
Africa
EMEA Generic Drug Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Pure (Non-branded) Generics
Branded Generics
Super Generics
EMEA Generic Drug Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Cardiovascular & Hypertension
Dermatology
Diabetes
Rheumatology
Oncology
Gastrointestinal
Others
EMEA Generic Drug Market: Players Segment Analysis (Company and Product introduction, Generic Drug Sales Volume, Revenue, Price and Gross Margin):
Teva Pharma.
Novartis company
Mylan
Allergan
Hospira
Dr. Reddy?s Lab.
Stada
Greenstone
Par Pharma
Sun Pharmaceutical
Aspen Pharmacare
Fresenius
Lupin
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF GENERIC DRUG
1.1 Definition of Generic Drug in This Report
1.2 Commercial Types of Generic Drug
1.2.1 Pure (Non-branded) Generics
1.2.2 Branded Generics
1.2.3 Super Generics
1.3 Downstream Application of Generic Drug
1.3.1 Cardiovascular & Hypertension
1.3.2 Dermatology
1.3.3 Diabetes
1.3.4 Rheumatology
1.3.5 Oncology
1.3.6 Gastrointestinal
1.3.7 Others
1.4 Development History of Generic Drug
1.5 Market Status and Trend of Generic Drug 2013-2023
1.5.1 EMEA Generic Drug Market Status and Trend 2013-2023
1.5.2 Regional Generic Drug Market Status and Trend 2013-2023
CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Generic Drug in EMEA 2013-2017
2.2 Consumption Market of Generic Drug in EMEA by Regions
2.2.1 Consumption Volume of Generic Drug in EMEA by Regions
2.2.2 Revenue of Generic Drug in EMEA by Regions
2.3 Market Analysis of Generic Drug in EMEA by Regions
2.3.1 Market Analysis of Generic Drug in Europe 2013-2017
2.3.2 Market Analysis of Generic Drug in Middle East 2013-2017
2.3.3 Market Analysis of Generic Drug in Africa 2013-2017
2.4 Market Development Forecast of Generic Drug in EMEA 2018-2023
2.4.1 Market Development Forecast of Generic Drug in EMEA 2018-2023
2.4.2 Market Development Forecast of Generic Drug by Regions 2018-2023
CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole EMEA Market Status by Types
3.1.1 Consumption Volume of Generic Drug in EMEA by Types
3.1.2 Revenue of Generic Drug in EMEA by Types
3.2 EMEA Market Status by Types in Major Countries
3.2.1 Market Status by Types in Europe
3.2.2 Market Status by Types in Middle East
3.2.3 Market Status by Types in Africa
3.3 Market Forecast of Generic Drug in EMEA by Types
CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Generic Drug in EMEA by Downstream Industry
4.2 Demand Volume of Generic Drug by Downstream Industry in Major Countries
4.2.1 Demand Volume of Generic Drug by Downstream Industry in Europe
4.2.2 Demand Volume of Generic Drug by Downstream Industry in Middle East
4.2.3 Demand Volume of Generic Drug by Downstream Industry in Africa
4.3 Market Forecast of Generic Drug in EMEA by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF GENERIC DRUG
5.1 EMEA Economy Situation and Trend Overview
5.2 Generic Drug Downstream Industry Situation and Trend Overview
CHAPTER 6 GENERIC DRUG MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA
6.1 Sales Volume of Generic Drug in EMEA by Major Players
6.2 Revenue of Generic Drug in EMEA by Major Players
6.3 Basic Information of Generic Drug by Major Players
6.3.1 Headquarters Location and Established Time of Generic Drug Major Players
6.3.2 Employees and Revenue Level of Generic Drug Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 GENERIC DRUG MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Teva Pharma.
7.1.1 Company profile
7.1.2 Representative Generic Drug Product
7.1.3 Generic Drug Sales, Revenue, Price and Gross Margin of Teva Pharma.
7.2 Novartis company
7.2.1 Company profile
7.2.2 Representative Generic Drug Product
7.2.3 Generic Drug Sales, Revenue, Price and Gross Margin of Novartis company
7.3 Mylan
7.3.1 Company profile
7.3.2 Representative Generic Drug Product
7.3.3 Generic Drug Sales, Revenue, Price and Gross Margin of Mylan
7.4 Allergan
7.4.1 Company profile
7.4.2 Representative Generic Drug Product
7.4.3 Generic Drug Sales, Revenue, Price and Gross Margin of Allergan
7.5 Hospira
7.5.1 Company profile
7.5.2 Representative Generic Drug Product
7.5.3 Generic Drug Sales, Revenue, Price and Gross Margin of Hospira
7.6 Dr. Reddy?s Lab.
7.6.1 Company profile
7.6.2 Representative Generic Drug Product
7.6.3 Generic Drug Sales, Revenue, Price and Gross Margin of Dr. Reddy?s Lab.
7.7 Stada
7.7.1 Company profile
7.7.2 Representative Generic Drug Product
7.7.3 Generic Drug Sales, Revenue, Price and Gross Margin of Stada
7.8 Greenstone
7.8.1 Company profile
7.8.2 Representative Generic Drug Product
7.8.3 Generic Drug Sales, Revenue, Price and Gross Margin of Greenstone
7.9 Par Pharma
7.9.1 Company profile
7.9.2 Representative Generic Drug Product
7.9.3 Generic Drug Sales, Revenue, Price and Gross Margin of Par Pharma
7.10 Sun Pharmaceutical
7.10.1 Company profile
7.10.2 Representative Generic Drug Product
7.10.3 Generic Drug Sales, Revenue, Price and Gross Margin of Sun Pharmaceutical
7.11 Aspen Pharmacare
7.11.1 Company profile
7.11.2 Representative Generic Drug Product
7.11.3 Generic Drug Sales, Revenue, Price and Gross Margin of Aspen Pharmacare
7.12 Fresenius
7.12.1 Company profile
7.12.2 Representative Generic Drug Product
7.12.3 Generic Drug Sales, Revenue, Price and Gross Margin of Fresenius
7.13 Lupin
7.13.1 Company profile
7.13.2 Representative Generic Drug Product
7.13.3 Generic Drug Sales, Revenue, Price and Gross Margin of Lupin
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF GENERIC DRUG
8.1 Industry Chain of Generic Drug
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF GENERIC DRUG
9.1 Cost Structure Analysis of Generic Drug
9.2 Raw Materials Cost Analysis of Generic Drug
9.3 Labor Cost Analysis of Generic Drug
9.4 Manufacturing Expenses Analysis of Generic Drug
CHAPTER 10 MARKETING STATUS ANALYSIS OF GENERIC DRUG
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Generic Drug in This Report
1.2 Commercial Types of Generic Drug
1.2.1 Pure (Non-branded) Generics
1.2.2 Branded Generics
1.2.3 Super Generics
1.3 Downstream Application of Generic Drug
1.3.1 Cardiovascular & Hypertension
1.3.2 Dermatology
1.3.3 Diabetes
1.3.4 Rheumatology
1.3.5 Oncology
1.3.6 Gastrointestinal
1.3.7 Others
1.4 Development History of Generic Drug
1.5 Market Status and Trend of Generic Drug 2013-2023
1.5.1 EMEA Generic Drug Market Status and Trend 2013-2023
1.5.2 Regional Generic Drug Market Status and Trend 2013-2023
CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Generic Drug in EMEA 2013-2017
2.2 Consumption Market of Generic Drug in EMEA by Regions
2.2.1 Consumption Volume of Generic Drug in EMEA by Regions
2.2.2 Revenue of Generic Drug in EMEA by Regions
2.3 Market Analysis of Generic Drug in EMEA by Regions
2.3.1 Market Analysis of Generic Drug in Europe 2013-2017
2.3.2 Market Analysis of Generic Drug in Middle East 2013-2017
2.3.3 Market Analysis of Generic Drug in Africa 2013-2017
2.4 Market Development Forecast of Generic Drug in EMEA 2018-2023
2.4.1 Market Development Forecast of Generic Drug in EMEA 2018-2023
2.4.2 Market Development Forecast of Generic Drug by Regions 2018-2023
CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole EMEA Market Status by Types
3.1.1 Consumption Volume of Generic Drug in EMEA by Types
3.1.2 Revenue of Generic Drug in EMEA by Types
3.2 EMEA Market Status by Types in Major Countries
3.2.1 Market Status by Types in Europe
3.2.2 Market Status by Types in Middle East
3.2.3 Market Status by Types in Africa
3.3 Market Forecast of Generic Drug in EMEA by Types
CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Generic Drug in EMEA by Downstream Industry
4.2 Demand Volume of Generic Drug by Downstream Industry in Major Countries
4.2.1 Demand Volume of Generic Drug by Downstream Industry in Europe
4.2.2 Demand Volume of Generic Drug by Downstream Industry in Middle East
4.2.3 Demand Volume of Generic Drug by Downstream Industry in Africa
4.3 Market Forecast of Generic Drug in EMEA by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF GENERIC DRUG
5.1 EMEA Economy Situation and Trend Overview
5.2 Generic Drug Downstream Industry Situation and Trend Overview
CHAPTER 6 GENERIC DRUG MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA
6.1 Sales Volume of Generic Drug in EMEA by Major Players
6.2 Revenue of Generic Drug in EMEA by Major Players
6.3 Basic Information of Generic Drug by Major Players
6.3.1 Headquarters Location and Established Time of Generic Drug Major Players
6.3.2 Employees and Revenue Level of Generic Drug Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 GENERIC DRUG MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Teva Pharma.
7.1.1 Company profile
7.1.2 Representative Generic Drug Product
7.1.3 Generic Drug Sales, Revenue, Price and Gross Margin of Teva Pharma.
7.2 Novartis company
7.2.1 Company profile
7.2.2 Representative Generic Drug Product
7.2.3 Generic Drug Sales, Revenue, Price and Gross Margin of Novartis company
7.3 Mylan
7.3.1 Company profile
7.3.2 Representative Generic Drug Product
7.3.3 Generic Drug Sales, Revenue, Price and Gross Margin of Mylan
7.4 Allergan
7.4.1 Company profile
7.4.2 Representative Generic Drug Product
7.4.3 Generic Drug Sales, Revenue, Price and Gross Margin of Allergan
7.5 Hospira
7.5.1 Company profile
7.5.2 Representative Generic Drug Product
7.5.3 Generic Drug Sales, Revenue, Price and Gross Margin of Hospira
7.6 Dr. Reddy?s Lab.
7.6.1 Company profile
7.6.2 Representative Generic Drug Product
7.6.3 Generic Drug Sales, Revenue, Price and Gross Margin of Dr. Reddy?s Lab.
7.7 Stada
7.7.1 Company profile
7.7.2 Representative Generic Drug Product
7.7.3 Generic Drug Sales, Revenue, Price and Gross Margin of Stada
7.8 Greenstone
7.8.1 Company profile
7.8.2 Representative Generic Drug Product
7.8.3 Generic Drug Sales, Revenue, Price and Gross Margin of Greenstone
7.9 Par Pharma
7.9.1 Company profile
7.9.2 Representative Generic Drug Product
7.9.3 Generic Drug Sales, Revenue, Price and Gross Margin of Par Pharma
7.10 Sun Pharmaceutical
7.10.1 Company profile
7.10.2 Representative Generic Drug Product
7.10.3 Generic Drug Sales, Revenue, Price and Gross Margin of Sun Pharmaceutical
7.11 Aspen Pharmacare
7.11.1 Company profile
7.11.2 Representative Generic Drug Product
7.11.3 Generic Drug Sales, Revenue, Price and Gross Margin of Aspen Pharmacare
7.12 Fresenius
7.12.1 Company profile
7.12.2 Representative Generic Drug Product
7.12.3 Generic Drug Sales, Revenue, Price and Gross Margin of Fresenius
7.13 Lupin
7.13.1 Company profile
7.13.2 Representative Generic Drug Product
7.13.3 Generic Drug Sales, Revenue, Price and Gross Margin of Lupin
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF GENERIC DRUG
8.1 Industry Chain of Generic Drug
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF GENERIC DRUG
9.1 Cost Structure Analysis of Generic Drug
9.2 Raw Materials Cost Analysis of Generic Drug
9.3 Labor Cost Analysis of Generic Drug
9.4 Manufacturing Expenses Analysis of Generic Drug
CHAPTER 10 MARKETING STATUS ANALYSIS OF GENERIC DRUG
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
